Centre for Genomic Regulation and Almirall join forces on skin cancer treatments
The collaboration aims to develop novel preclinical models with a view to identifying new treatments
Read More
Tag: Almirall
Almirall analyses wider well-being in dermatology study
The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab
Read More
Almirall joins project to allow study participants to use trial data
Project involves 27 partners including patient associations, hospitals and universities
Read More
Lebrikizumab shows improvements in late-stage eczema trial
Endpoints of improved skin clearance, itch and quality of life were met
Read More
NICE backs Cimzia for psoriasis, but rejects Ilumetri
Cost watchdog the National Institute for Health and Care Excellence has backed NHS funding for UCB’s Cimzia as a treatment for psoriasis, but is not recommending Almirall’s Ilumetri.
Read More
Almirall steps into psoriasis market with Ilumetri approval
The European Commission has approved Almirall’s Ilumetri for moderate-to-severe chronic plaque psoriasis.
Read More
NICE backs new treatment option for psoriasis
The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
Read More
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
